High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance.

Machine translation Machine translation
类别 Primary study
期刊Journal of viral hepatitis
Year 2004
在B型肝炎病毒与拉米夫定治疗的患者的耐药性病毒的出现,是有据可查的。然而,其在抗-HBe阳性代偿期肝硬化患者的长期治疗的临床影响是不为人所熟知。在这项研究中,我们治疗22例抗-HBe补偿与拉米夫定治疗肝硬化,中位数为42个月期间。所有患者对拉米夫定,但病毒的突破发生在13例9和第42个月的治疗,由于出现突变株(59%)之间。在后续行动,11个发达肝癌。其中,10发生后不久,出现病毒耐药,普遍表现出过激的行为,并在九长期的应答者(P = 0.013)。拉米夫定耐药肝癌发展的唯一独立预测因子(风险比率:10.4,95%CI:1.3-84.9)。我们的研究表明,拉米夫定耐药的发生,增加了抗-HBe阳性肝硬化和值得进一步研究肝癌癌的风险。
Epistemonikos ID: 6d4c6680f86da9f8b23ce36dbe2d2c6d93dfdcaa
First added on: Jun 08, 2011
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use